Negotiations on Drug Prices in China and Health Insurance Sustainability: Retrospective and Future Trends
Abstract
Objective: This study examines the drug price negotiation process in China from 2017 to 2023, with a particular focus on its impact on drug pricing, especially for innovative therapies, and its influence on healthcare affordability and the sustainability of the health insurance system.
Material and Methods: Data were sourced from public reports and official announcements by the National Healthcare Security Administration (NHSA). A mixed-method approach was employed, combining quantitative analysis of price reductions, success rates, and healthcare expenditure with qualitative insights into policy challenges, focusing on high-cost treatments like oncology drugs and innovative therapies.
Results: From 2017 to 2023, price negotiations led to average reductions of 50-62%, with oncology drugs experiencing a maximum price reduction of 94%. The efficiency of negotiations improved significantly, with a success rate of 85% by 2023. These reductions enhanced access to costly treatments, particularly cancer therapies, but rising demand for innovative treatments continued to strain the healthcare budget. The inclusion of more high-cost therapies in the National Reimbursement Drug List (NRDL) further contributed to the growth in expenditure. Additionally, the proportion of domestically produced drugs in negotiations increased from 39% in 2021 to 69% in 2023, reflecting efforts to enhance self-sufficiency.
Conclusion: Negotiations on drug prices in China have effectively reduced drug prices and improved access to critical therapies, such as innovative and life-saving treatments. However, ongoing demand for innovative treatments poses challenges to the financial sustainability of the health insurance system. Further improvements in value-based pricing and regulatory frameworks are needed to maintain affordability and foster innovation.
Keywords
Full Text:
PDFReferences
Liu GG, Wu J, He X, Jiang Y. Policy updates on access to and affordability of innovative medicines in china. Value Health Reg Issues 2022;30:59–66. doi: 10.1016/j.vhri.2021.12.003.
Kaltenboeck A, Bach PB. Value-based pricing for drugs: theme and variations. JAMA 2018;319:2165–6. doi: 10.1001/jama.2018.4871.
Vogler S, Paris V, Panteli D. Ensuring access to medicines: How to redesign pricing, reimbursement and procurement?. Geneva, Switzerland: World Health Organization, Regional Office for Europe; 2018.
Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global Cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2021;71:209-49.
Tang M, Song P, He J. Progress on drug pricing negotiations in China. Biosci Trends 2020;13:464–8. doi: 10.5582/bst.2019.01339.
Guan X, Liang H, Xue Y, Shi L. An analysis of China’s national essential medicines policy. J Public Health Policy 2011;32:305-19.
Zhang Y, Chen Z, Li J. The current status of treatment for colorectal cancer in China: a systematic review. Medicine 2017;96:e8242.
Cao W, Chen HD, Yu YW, Li N, Chen WQ. Changing profiles of cancer burden worldwide and in China: a secondary analysis of the global cancer statistics 2020. Chin Med J 2021;134:783-91.
Diao Y, Li M, Huang Z, Sun J, Chee YL, Liu Y. Unlocking access to novel medicines in China - a review from a health system perspective. Risk Manag Healthc Policy 2019;12:357-67.
Peng Yunjia. “Difficult to enter the hospital” for medical insurance drugs? “Dual channel” Liangjian enters the hospital for the “last mile”. [homepage on the Internet]. Beijing: Xinhua News Agency; 2021. [cited 2022 Jun 20]. Available from: http://www.gov.cn/xinwen/2021-05/10/content_5605635.htm
Chen W, Jiang Z, Shao Z, Sun Q, Shen K. An economic evaluation of adjuvant trastuzumab therapy in HER2-Positive early breast cancer. Value Health 2009;12:S82-4.
National Medical Security Administration. Announcement of the national medical security administration on publishing the “national medical insurance drug catalog adjustment work plan in 2021” and “national medical insurance drug catalog adjustment application guidelines”. [homepage on the Internet]. Beijing: National Healthcare Security Administration; 2021 [cited 2023 May 01]. Available from: http://www.nhsa.gov.cn/art/2021/6/30/art_62_5386.html
Li G, Liu Y, Xie C, Zhou Q, Chen X. Characteristics of expedited programmes for cancer drug approval in China. Nat Rev Drug Discov 2021;20:416. doi: 10.1038/d41573-021-00080-0.
Salas-Vega S, Shearer E, Mossialos E. Relationship between costs and clinical benefits of new cancer medicines in Australia, France, the UK, and the US. Soc Sci Med 2020;258:113042. doi: 10.1016/j.socscimed.2020.113042.
Liu Y, Zhang N, Xie C, Jiang Y, Qin Y, Zhou L, et al. Evolution of drug regulations and regulatory innovation for anticancer drugs in China. Acta Pharm Sin B 2022;12:4365–77. doi: 10.1016/j.apsb.2022.08.004.
Zhu H, Zhu J, Zhou Y, Shan L, Li C, Cui Y, et al. Impact of the national reimbursement drug list negotiation policy on accessibility of anticancer drugs in China: an interrupted time series study. Front Public Health 2022;10:921093. doi: 10.3389/fpubh.2022.921093.
Fang W, Xu X, Zhu Y, Dai H, Shang L, Li X. Impact of the national health insurance coverage policy on the utilisation and accessibility of innovative anti-cancer medicines in China: an interrupted time-series study. Front Public Health 2021;9:714127. doi: 10.3389/fpubh.2021.714127.
Villa F, Tutone M, Altamura G, Antignani S, Cangini A, Fortino I, et al. Determinants of price negotiations for new drugs. The experience of the Italian Medicines Agency. Health Policy 2019;123:595-600.
Moye-Holz D, van Dijk JP, Reijneveld SA, Hogerzeil HV. The impact of price negotiations on public procurement prices and access to 8 innovative cancer medicines in a middle-income country: the case of Mexico. Value Health Reg Issues 2019;20:129-35.
Zhang Y, Wushouer H, Han S, Fu M, Guan X, Shi L, et al. The impacts of government reimbursement negotiation on targeted anticancer medication price, volume and spending in China. BMJ Glob Health 2021;6. doi: 10.1136/bmjgh-2021-006196.
The National Healthcare Security Administration. Interim measures for the administration of use of drugs covered by the basic medical insurance [homepage on the Internet]. Beijing: National Healthcare Security Administration; 2020 [cited 2022 Jun 14]. Available from: http://www.gov.cn/zhengce/zhengceku/2020-08/04/content_5532409.htm
Vokinger KN, Hwang TJ, Grischott T, Reichert S, Tibau A, Rosemann T, et al. Prices and clinical benefit of cancer drugs in the USA and Europe: a cost–benefit analysis. Lancet Oncol 2020;21:664–70. doi: 10.1016/S1470-2045(20)30139-X.
Kovic B, Jin X, Kennedy SA, Hylands M, Pedziwiatr M, Kuriyama A, et al. Evaluating progression-free survival as a surrogate outcome for health-related quality of life in oncology: a systematic review and quantitative analysis. JAMA Intern Med 2018;178:1586–96. doi: 10.1001/jamainternmed.2018.4710.
Zhang J. Application and approval of cancer drugs in China: acceleration should be kept in progress. AME Med J 2018;3:57-7.
Kovic B, Jin X, Kennedy SA, Hylands M, Pedziwiatr M, Kuriyama A, et al. Evaluating progression-free survival as a surrogate outcome for health-related quality of life in oncology: a systematic review and quantitative analysis. JAMA Intern Med 2018;178:1586–96. doi: 10.1001/jamainternmed.2018.4710.
Vallano A, Pontes C. Escalating costs of innovative medicines: perspective and proposals. Front Public Health 2024;12:1449707. doi: 10.3389/fpubh.2024.1449707.
Li M, Diao Y, Ye J, Sun J, Jiang Y.The public health insurance coverage of novel targeted anticancer medicines in China-in favor of whom? A retrospective analysis of the insurance claim data. Front Pharmacol 2021;12:778940.
Diao Y, Qian J, Liu Y, Zhou Y, Wang Y, Ma H, et al. How government insurance coverage changed the utilization and affordability of expensive targeted anti-cancer medicines in China: an interrupted time-series study. J Glob Health 2019;9:020702.
Zhang B, Ding J, Chen Y, Wei L. Research on the policy motivation and implementation model of “dual channel” management mechanism for national reimbursement negotiation drugs. World Clin Drugs 2021;42:9.
Russo P, Marcellusi A, Zanuzzi M, Carletto A, Fratto ME, Favato G, et al. Drug prices and value of oncology drugs in Italy. Value Health 2021;24:1273–8. doi: 10.1016/j.jval.2021.04.1278.
National Healthcare Security Administration. Press conference: safeguarding people’s health and empowering economic development. [homepage on the Internet]. Beijing: National Healthcare Security Administration; 2025. [cited 2025 Feb 5]. https://www.nhsa.gov.cn/art/2025/1/17/art_14_15491.html
National Healthcare Security Administration. Statistical bulletin on the development of medical insurance in 2023. [homepage on the Internet]. Beijing: Economic Observer; 2024 [cited 2025 Jun 6]. Available from: http://www.eeo.com.cn/2024/0420/653838.shtml
Huang Y. China’s emerging welfare crisis [homepage on the Internet]. Beijing: Think Global Health; 2024 [cited 2025 Jun 6]. Available from: https://www.thinkglobalhealth.org/article/chinas-emerging-welfare-crisis
Gregson N, Sparrowhawk K, Mauskopf J, Paul J. Pricing medicines: theory and practice, challenges and opportunities. Nat Rev Drug Discov 2005;4:121–30. doi: 10.1038/nrd1633.
Li T, Li X. Does structural deceleration happen in China? Evidence from the effect of industrial structure on economic growth quality. Natl Account Rev 2020;2:155–73. doi: 10.3934/NAR.2020009.
Si L, Xu L, Chen M, Jan S. Using strategic price negotiations to contain costs and expand access to medicines in China. BMJ Glob Health 2020;5:e002256.
Henry Ntarmah A, Kong Y, Kobina Gyan M. Banking system stability and economic sustainability: a panel data analysis of the effect of banking system stability on sustainability of some selected developing countries. Quant Financ Econ 2019;3:709–38. doi: 10.3934/QFE.2019.4.709.
Jiang J, Zhang X. Social transition and health inequality in China: an age-period-cohort analysis. Public Health 2020;180:185–95. doi: 10.1016/j.puhe.2019.08.025.
Bloomberg News. China pledges key reforms to revamp nation’s medical system [homepage on the Internet]. NYC: Bloomberg; 2024 [cited 2025 Jun 6]. Available from: https://www.bloomberg.com/news/articles/2024-06-06/china-pledges-key-reforms-to-revamp-nation-s-medical-system
National Healthcare Security Administration. Press conference: safeguarding people’s health and empowering economic development [homepage on the Internet]. Beijing: National Healthcare Security Administration; 2025 [cited 2025 Feb 5]. Available from: https://www.nhsa.gov.cn/art/2025/1/17/art_14_15491.html
Refbacks
- There are currently no refbacks.
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.